The other day I was reading an interesting article on Defensive Due Diligence by Claudine Cohen, Mendy Dwestel and Andrew Finkle (all from Grant Thornton) in the January 2010 of Mergers & Acquisitions publication of the Association for Corporate Growth. They make...
It seems my industry colleagues have been wrongly optimistic and also hyper cynical. At least that is the bottom line of the read I get in comparing the analysis of the 2nd annual Semaphore Confidence Survey with last year’s results. And some people have very...
The Valley of Death for a Life Sciences company is that space, as coined by the NCI’s Director of Small Business Innovation Research Programs Michael Weingarten, between a Phase 2 SBIR grant and the commercial success of the technology that is being funded and...
Though only 177 of the total 258 Olympic medals have been awarded so far, with Germany and the United States still battling for medal supremacy (as of February 23, the US had 26 medals and Germany 23), the real winner of the 2010 games has already been decided :...
So what’s wrong with Biotech financing today? What will it take to bring the Biotech market out of the doldrums and back into action? If you are having trouble finding financing for your next greatest idea then the only comforting news is that you are not alone....
Blog Series: 1 of 4 When it comes to venture capital and growth equity investments, the bottom line is the top line. If a company can grow its revenue, then odds are it will generate a strong return for its investors. Market due diligence is a key component of...
